IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 24.12

Change

+0.37 (+1.56)%

Market Cap

USD 0.14B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.04 (+0.03%)

USD 37.76B
VHT Vanguard Health Care Index Fun..

+0.08 (+0.03%)

USD 16.98B
XBI SPDR® S&P Biotech ETF

+1.27 (+1.54%)

USD 7.05B
IHI iShares U.S. Medical Devices E..

+0.26 (+0.47%)

USD 5.55B
IXJ iShares Global Healthcare ETF

+0.21 (+0.24%)

USD 4.11B
IYH iShares U.S. Healthcare ETF

-0.07 (-0.12%)

USD 3.23B
FHLC Fidelity® MSCI Health Care In..

+0.10 (+0.15%)

USD 2.94B
FXH First Trust Health Care AlphaD..

+0.18 (+0.17%)

USD 1.33B
FBT First Trust NYSE Arca Biotechn..

+1.06 (+0.74%)

USD 1.08B
IHF iShares U.S. Healthcare Provid..

-0.19 (-0.36%)

USD 0.82B

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.82% 41% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.82% 41% F 54% F
Trailing 12 Months  
Capital Gain 4.19% 23% F 40% F
Dividend Return 1.04% 63% D 12% F
Total Return 5.23% 27% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 9% A- 47% F
Dividend Return 1.57% 9% A- 37% F
Total Return 0.37% 45% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 37.98% 9% A- 27% F
Risk Adjusted Return 4.13% 9% A- 31% F
Market Capitalization 0.14B 27% F 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.